Primary Biliary Cholangitis
An autoimmune liver disease where the immune system slowly attacks the small bile ducts in the liver, leading to bile buildup, severe itching, and fatigue.
Emergency Management: Acute variceal hemorrhage in a patient who has progressed to cirrhosis requires emergent stabilization, IV octreotide, prophylactic antibiotics (Ceftriaxone), and urgent therapeutic endoscopy for variceal band ligation.
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive, immune-mediated destruction of small intrahepatic bile ducts, leading to cholestasis, fibrosis, and potentially cirrhosis.
Detailed Overview
PBC predominantly affects middle-aged women. The serologic hallmark is the presence of anti-mitochondrial antibodies (AMA). The destruction of interlobular bile ducts impairs the flow of bile (cholestasis), causing retention of toxic bile acids in the liver which promotes hepatocyte apoptosis and progressive scarring. While formerly known as Primary Biliary 'Cirrhosis', the name was changed because early diagnosis and treatment with Ursodeoxycholic acid (UDCA) can halt progression, meaning many patients never actually develop cirrhosis.
Epidemiology & Demographics
Prevalence is approximately 30-40 per 100,000. Striking female predominance (female to male ratio of 9:1 to 10:1). Typical age of onset is 40 to 60 years.
Etiological Mechanism
Considered an autoimmune disorder triggered by environmental factors (e.g., urinary tract infections, xenobiotics, smoking) in genetically susceptible individuals (associated with HLA alleles).
Primary Causes
Autoreactive T-cells mistakenly target the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) located on the biliary epithelial cells.
The primary defect is a loss of immune tolerance to mitochondrial antigens, specifically PDC-E2. CD4+ and CD8+ T-cells infiltrate the portal tracts and directly attack cholangiocytes lining the small and medium-sized intrahepatic bile ducts. This creates granulomatous inflammation (florid duct lesion). The destruction of these ducts causes profound cholestasis. The retained lipophilic bile acids accumulate in the liver, causing hepatocyte necrosis and apoptosis. Chronic inflammation activates hepatic stellate cells, which lay down collagen, leading to progressive portal fibrosis, bridging fibrosis, and eventually micronodular cirrhosis.
Diagnostic Criteria & Guidelines
Diagnosis is confirmed if 2 out of 3 criteria are met: 1) Biochemical evidence of cholestasis (elevated Alkaline Phosphatase) for >6 months. 2) Presence of Anti-Mitochondrial Antibodies (AMA) at a titer >1:40. 3) Histologic evidence of non-suppurative destructive cholangitis (liver biopsy is not strictly required if the first two are met).
Ursodeoxycholic acid (UDCA) 13-15 mg/kg/day orally in divided doses. UDCA is a hydrophilic, non-toxic bile acid that displaces toxic endogenous bile acids, improves biliary secretion, and delays disease progression. Must be continued lifelong.
Second-Line & Adjunctive Therapy
For patients with inadequate response to UDCA after 1 year (ALP > 1.6x ULN): Obeticholic acid (5 mg daily up to 10 mg daily), an FXR agonist. Fibrates (e.g., Bezafibrate) are also increasingly used off-label. For Pruritus: Cholestyramine 4g PO before meals, or Rifampin 150 mg BID.
Surgical & Procedural Management
Liver transplantation is the definitive treatment for decompensated cirrhosis (MELD score >15) or intractable pruritus failing all medical therapy. 1-year post-transplant survival is excellent (>90%).
Patient Counseling & Advice
Inform patients that while UDCA dramatically slows the disease, it does not cure it and may not relieve the fatigue or itching. Explain that separate medications are needed to manage the itching.
Follow-Up & Monitoring Schedule
Liver chemistries (ALP, Bilirubin, AST/ALT) every 3-6 months. DEXA scan every 2 years to monitor bone density. Annual ultrasound screening for hepatocellular carcinoma once cirrhosis is established.
Preventive Strategies
No primary prevention exists due to the autoimmune nature. Secondary prevention of progression relies entirely on early initiation and strict adherence to UDCA.
If diagnosed early and treated effectively with UDCA, life expectancy is comparable to the general population. If left untreated or unresponsive to UDCA, average survival is 7-10 years from the onset of symptoms.